Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test].

L'Encephale - 1 Jan 2000

Baumann P

Abstract excerpt

The drug monitoring of antidepressants in blood plasma has revealed considerable interindividual differences in steady-state levels. For some compounds recent results strongly suggest that this phenomenon finds an explanation in genetic differences in the metabolism of the drugs by monooxygenases (cytochrome P-450) in the liver. Thus, a genetic deficiency has been described in 5-10% of the European population in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to Cytochrome P-450 Enzyme System

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Debrisoquin

Share to Depressive Disorder

Share to Hydroxylation

Share to Phenotype

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 3792273

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test].PMID 3792273Read ↗

[Debrisoquine hydroxylation test as an example of new possibilities of research in psychopharmacology].Semantic proximity Read ↗

[CYP2D6 gene polymorphism in psychiatric patients resistant to standard pharmacotherapy].Semantic proximity Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.Semantic proximity Read ↗

Pharmacogenetics of antidepressants: clinical aspects.Semantic proximity Read ↗

Clinical consequences of polymorphic drug oxidation.Semantic proximity Read ↗

Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.Semantic proximity Read ↗

[Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].Semantic proximity Read ↗

[Knowledge about metabolic capacity is important in drug therapy].Semantic proximity Read ↗

Genetically determined adverse drug reactions involving metabolism.Semantic proximity Read ↗

Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.Semantic proximity Read ↗

Debrisoquine and dextromethorphan phenotyping and antidepressant treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.